Kirk Sanford
Longevity Medical Institute, San José del Cabo, Baja California Sur, Mexico, Longevity Medical Institute, Houston, TX, United States
Publications
-
Research Article
Safety of Allogeneic Mesenchymal Stromal Cell Therapy Across Human Clinical Indications: A Systematic Review of Landmark Clinical Trials and Published Safety Evidence
Author(s): Kirk Sanford*, Felix Porras, Fergie Martinez, Hugo Ramos, Janine Zamitiz, Carlos Green and Edward Ramsay
Background: Allogeneic mesenchymal stromal cells (MSCs) have emerged as an off-the-shelf regenerative medicine platform across cardiovascular, pulmonary, musculoskeletal, autoimmune, gastrointestinal, and renal indications. Although individual clinical trials frequently describe favorable tolerability, safety reporting remains heterogeneous across studies, and the adverse event profile of allogeneic MSC administration has not been consistently synthesized with emphasis on treatment-related serious toxicity. Landmark MSC safety meta-analyses have generally concluded that MSC therapy appears safe, with transient fever representing the most reproducible treatment-associated event. Objective: To evaluate the safety profile of allogeneic mesenchymal stromal cell therapy across human clinical indications, with emphasis on treatment-relat.. Read More»